JP7528065B2 - Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 - Google Patents

Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 Download PDF

Info

Publication number
JP7528065B2
JP7528065B2 JP2021517342A JP2021517342A JP7528065B2 JP 7528065 B2 JP7528065 B2 JP 7528065B2 JP 2021517342 A JP2021517342 A JP 2021517342A JP 2021517342 A JP2021517342 A JP 2021517342A JP 7528065 B2 JP7528065 B2 JP 7528065B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
group
compound
residues selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502441A5 (https=
JP2022502441A (ja
Inventor
ピー． ブライスウェイト，スティーブン
ミナミ，エス．サクラ
ニコリッチ，カロリー
ヴィ． レージ，サンケット
イー．ジェー． テイシェール，アマウド
Original Assignee
アルカヘスト，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカヘスト，インコーポレイテッド filed Critical アルカヘスト，インコーポレイテッド
Publication of JP2022502441A publication Critical patent/JP2022502441A/ja
Publication of JP2022502441A5 publication Critical patent/JP2022502441A5/ja
Priority to JP2024118649A priority Critical patent/JP2024153742A/ja
Application granted granted Critical
Publication of JP7528065B2 publication Critical patent/JP7528065B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021517342A 2018-09-26 2019-09-25 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 Active JP7528065B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024118649A JP2024153742A (ja) 2018-09-26 2024-07-24 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
US62/737,017 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024118649A Division JP2024153742A (ja) 2018-09-26 2024-07-24 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2022502441A JP2022502441A (ja) 2022-01-11
JP2022502441A5 JP2022502441A5 (https=) 2022-09-14
JP7528065B2 true JP7528065B2 (ja) 2024-08-05

Family

ID=69953286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517342A Active JP7528065B2 (ja) 2018-09-26 2019-09-25 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
JP2024118649A Pending JP2024153742A (ja) 2018-09-26 2024-07-24 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024118649A Pending JP2024153742A (ja) 2018-09-26 2024-07-24 Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Country Status (15)

Country Link
EP (1) EP3856195A4 (https=)
JP (2) JP7528065B2 (https=)
KR (1) KR20210065950A (https=)
CN (1) CN112789044A (https=)
AU (1) AU2019346456A1 (https=)
BR (1) BR112021004938A2 (https=)
CL (1) CL2021000724A1 (https=)
CO (1) CO2021003713A2 (https=)
EA (1) EA202190463A1 (https=)
IL (1) IL281578A (https=)
MA (1) MA53743A (https=)
MX (1) MX2021002967A (https=)
SG (1) SG11202102105VA (https=)
TW (1) TW202027752A (https=)
WO (1) WO2020069008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113689A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514024A (ja) 2009-04-08 2012-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３アンタゴニストとしての置換ピペリジン
JP2012524790A (ja) 2009-04-22 2012-10-18 アクシキン ファーマシューティカルズ インコーポレーテッド ２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト
JP2013542207A (ja) 2010-10-07 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３インヒビターの共結晶及び塩
JP2015512433A (ja) 2012-04-04 2015-04-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３アンタゴニストを含む医薬製剤
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
MY199462A (en) * 2017-04-05 2023-10-30 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514024A (ja) 2009-04-08 2012-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３アンタゴニストとしての置換ピペリジン
JP2012524790A (ja) 2009-04-22 2012-10-18 アクシキン ファーマシューティカルズ インコーポレーテッド ２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
JP2013542207A (ja) 2010-10-07 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３インヒビターの共結晶及び塩
JP2015512433A (ja) 2012-04-04 2015-04-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ３アンタゴニストを含む医薬製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. Banisadr et al.，Current Drug Targets - Inflammation & Allergy，2005年，Vol.4，pp.387-399.

Also Published As

Publication number Publication date
BR112021004938A2 (pt) 2021-06-01
MA53743A (fr) 2022-01-05
TW202027752A (zh) 2020-08-01
CO2021003713A2 (es) 2021-04-08
AU2019346456A1 (en) 2021-04-15
KR20210065950A (ko) 2021-06-04
JP2024153742A (ja) 2024-10-29
EP3856195A4 (en) 2022-06-22
CN112789044A (zh) 2021-05-11
EA202190463A1 (ru) 2021-06-29
CL2021000724A1 (es) 2021-10-15
SG11202102105VA (en) 2021-04-29
MX2021002967A (es) 2021-08-11
IL281578A (en) 2021-05-31
JP2022502441A (ja) 2022-01-11
CA3111433A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
WO2020069008A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
JP2020530847A (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
CN114340670A (zh) T-型钙通道调节剂的制剂及其使用方法
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
AU2016226006A1 (en) Method of treatment with tradipitant
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
CN115776894A (zh) T型钙通道调节剂的使用方法
JP2016216438A (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
CA3111433C (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
US20200360460A1 (en) Neuroprotective peptide
US20230127694A1 (en) Neuroprotective peptide
WO2025188952A1 (en) Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
TW202539621A (zh) 用於治療巴金森氏症的治療劑
JP6738797B2 (ja) レット症候群治療薬
WO2014091430A1 (es) Composición farmacéutica de una meglitinida y una tiazolidinediona y su uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7528065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150